Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
AB Sciex
RANDOX LABORATORIES

Whole-Genome Testing Helps Identify Breast Cancer Treatments

By Labmedica International staff writers
Posted on 26 Feb 2014
Image: The Qubit fluorometer (Photo courtesy of Life Technologies).
Image: The Qubit fluorometer (Photo courtesy of Life Technologies).
A molecular screening study has identified abnormalities in individual patients with breast cancer with the aim of providing targeted therapy matched to individuals' genomic alterations.

Progress in developing effective new chemotherapy or hormonal therapies for metastatic cancer has been slow, though there have been developments in therapies targeting specific genetic mutations in breast cancer.

In a multicenter, prospective trial scientists at the Institute Gustave Roussy (Villejuif, France) and colleagues from other institutions recruited 423 patients who had breast cancer with a metastasis accessible for biopsy in 18 centers in France, from June 16, 2011, to July 30, 2012. Comparative genomic hybridization (CGH) array and Sanger sequencing on phosphatidylinositol-4,5 -bisphosphate 3-kinase, (PIK3CA, exon 10 and 21) and v-akt murine thymoma viral oncogene homolog 1 (AKT1, exon 4) were used to assess metastatic biopsy samples from five medical centers.

DNA concentration was measured with Qubit 2.0 Fluorometer (Life Technologies; Paisley, UK) and sequencing was performed with Life Technologies' BigDye Terminator Cycle Sequencing Kit. For genomic analyses on microarray platforms (Agilent Technologies; Massy, France) tumor and control DNA were labeled by random priming, and then hybridized. To assess robustness of data, normal genomic DNA was used in all analyses to validate the genomic profile findings in tumor samples.

Examining the DNA from the samples, the team found that just under half (46%) of the patients in the study had a genomic alteration that could be targeted, while 39% had rare alterations for which no treatments currently exist. Therapy could be personalized in 55 (13%) of 423 patients. Of the 43 patients who were assessable and received targeted therapy, four (9%) had an objective response, and nine others (21%) had stable disease for more than 16 weeks.

Fabrice André MD, a professor and lead author said, "So far 55 of those enrolled, which is 28% of those with targetable alterations, have been matched with new treatments being tested in clinical trials. This emphasizes the need to increase the range of drug trials. Our goal is to have 30% of patients in clinical trials testing therapies targeting the alterations identified in their tumors." The study was published on February 7, 2014, in the journal Lancet Oncology.

Related Links:

Institute Gustave Roussy
Life Technologies
Agilent Technologies



DiagCor Bioscience
ADVANCED INSTRUMENTS
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.